Michael Callahan, MD
Gynecologic Oncology · Indianapolis, INNPI 1548396492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Merck at 40.3% of the total. That places this record below the midpoint for gynecologic oncology clinicians in IN, where the typical reported total is $1,688.
Across 12 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$92
- Eisai Inc.$47
- Daiichi Sankyo Inc.$24
- Hologic Sales And Service, LLC$22
- Smith+Nephew$17
- Clovis Oncology, Inc.$15
- plus $11 from 1 others
Across 190 payments — averaging $10,099 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- GSK$253K
- Tesaro, Inc.$133K
- AstraZeneca$78K
- Genentech, Inc.$69K
- Karyopharm Therapeutics Inc.$53K
- plus $55K from 3 others
What the payments were for
- Food & beverage$21192%
- Education$188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 5 | $92 |
| Eisai Inc. | 2 | $47 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Smith+Nephew | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $15 |
| Davol Inc. | 1 | $11 |
How this compares
$229 in reported general payments places this provider in the 10th percentile of 26 gynecologic oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 11 | $203,267 |
| Ondansetron OdtOndansetron | 27 | $460 |
| Letrozole | 30 | $450 |
| Anastrozole | 16 | $192 |
| Prochlorperazine Maleate | 12 | $180 |
| Megestrol Acetate | 12 | $164 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 14 | $71 |
| Tamoxifen Citrate | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Indianapolis
- Jessica Parker MetterIndianapolis$6K
- Hilary HinshawIndianapolis$5K
- Lisa LandrumIndianapolis$4K
- James DunlopIndianapolis$3K
- Tina AyeniIndianapolis$2K
- James CripeIndianapolis$2K
- Michael MethodIndianapolis$2K
- Sharon RobertsonIndianapolis$2K
- Hubert FornalikIndianapolis$1K
- Sarah GoodrichIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.